• Patients
  • Health Information
  • Product Information Request
  • Our Products
  • CephalonCares Foundation Patient Assistance Programs
  • Reimbursement Assistance
  • Clinical Trials Information
  • Healthcare Professionals
  • Therapeutic Focus
  • Product Information Request
  • Our Products
  • CephalonCares Foundation Patient Assistance Programs
  • Reimbursement Assistance
  • Clinical Trials Information
  • Partners
  • Business Collaboration
  • Research Partnerships
  • Investors
  • Overview
  • News Releases
  • SEC Filings
  • Stock Information
  • Dividend/Split History
  • Corporate Governance
  • Financial Reports
  • Analyst Coverage
  • Ownership Profile
  • Investor Events
  • Webcasts and Presentations
  • Investor FAQ
  • Literature Request
  • Email Alerts
  • Media
  • News Releases
  • Media Resources
  • Featured Profiles
  • On The Record
  • Our Company
  • Message from the Chairman/CEO
  • Our Story
  • Our Team
  • Awards & Recognition
  • Our Science
  • Our Scientists
  • R&D Process
  • Clinical Trials
  • Pipeline
  • Our Responsibility
  • Business Conduct
  • Relationships with Healthcare Professionals
  • CephalonCares Foundation
  • Commitment to Community
  • Careers
  • Employee Benefits
  • Job Listings
  • Contact Us
  • Cephalon Websites
  • Terms of Use
  • Privacy
Cephalon
  • Home
  • Contact Us
  • Cephalon Websites
  • CephalonCares Foundation
  • Sitemap
  • Our Company
  • Our Science
  • Our Responsibility
  • Careers
  • Patients
  • Healthcare Professionals
  • Partners
  • Investors
  • Media
Search Site

  • Media
  • News Releases
    • By Year
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
      • 2004
  • Media Resources
    • Corporate
    • Central Nervous System Disorders
    • Cancer
    • Pain
  • Featured Profiles
    • Healthcare Professionals
    • Programs
    • Products
  • On The Record
    • Cephalon Response to JAMA Article “The Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain”
    • Archive
      • Q&A on Settlements Regarding Investigations into Cephalon Business Practices
      • Our Commitment to Appropriate Interactions with Healthcare Professionals
      • Our Position on Tamper-Deterrent Formulation of Extended-Release Opioids
      • Set the Record Straight About ACTIQ®
      • Set the Record Straight About PROVIGIL®

header image

Home > Media > Media Resources > Cancer

Cancer

Media Contact:

Jenifer Antonacci
Associate Director,
Product Communications
Phone: 610-738-6674
Fax: 610-344-0981
After hours:
610-457-7059
jantonac@cephalon.com

logo
TREANDA® Press Kit
  • Prescribing Information
  • Press Releases
  • TREANDA Fact Sheet

Multimedia Files

  • TREANDA Packaging photo (.jpg)
  • TREANDA Proposed Mechanism of Action (.jpg)
  • TREANDA Proposed Mechanism of Action (.tif)

Background Documents

  • Disease State Fact Sheets
logo
TRISENOX® Press Kit
  • Prescribing Information, including box warning
  • Press Releases
  • TRISENOX Fact Sheet

Multimedia Files

  • TRISENOX photo (.jpg)

Background Documents

  • Disease State Fact Sheet
 
Cephalon Oncology Clinical Development Press Kit

Background Documents

  • Oncology Clinical Development Pipeline
Heading 5

Sidebar Text area

  • Copyright 2010. Cephalon, Inc. All Rights Reserved.
    • Terms of Use
    • Privacy